-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70

Benzinga·11/04/2026 15:52:37
Diffusion vocale
Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.